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Hepatitis B virus (HBV) infection after liver transplanta-
tion (LT) may lead to severe and rapidly progressive graft
failure. Antiviral treatment may be of benefit in selected
patients with recurrent hepatitis B post-LT. The aim of
this prospective open-label study is to determine the safety
and efficacy of lamivudine in 33 liver transplant recipients
with active HBV infection. The median time from LT to
study enrollment was 51 months, all patients were hepa-
titis B surface antigen positive, and 75% and 94% of
subjects had detectable hepatitis B e antigen (HBeAg) and
HBV DNA at entry, respectively. The median duration of
lamivudine treatment on study was 85 weeks, during
which time median HBV DNA levels became undetectable
by 16 weeks and 9% of patients lost previously detectable
HBeAg. Serum alanine aminotransferase (ALT) levels im-
proved in most patients and normalized in 27% of pa-
tients with elevated values pretreatment. Serum bilirubin
and albumin levels significantly improved in patients with
abnormal values at entry (P < .05). Virological break-
through was detected in 13 subjects after a median of 61
weeks of lamivudine treatment and was confirmed to be
caused by YMDD mutants in all patients tested. None of
the patients with virological breakthrough showed a com-
plete loss of clinical response to lamivudine. Serum ALT
and bilirubin levels in patients with and without virolog-
ical breakthrough were not significantly different at last
study follow-up. Study results show that lamivudine is
safe and effective in liver transplant recipients with recur-
rent hepatitis B. However, the high rate of virological
breakthrough with prolonged therapy indicates the need
for further studies of combination antiviral therapy in this
patient population. Our results and others further estab-
lish the improving long-term outcomes with LT for pa-
tients with hepatitis B through advances in prevention of
reinfection, as well as the availability of safe and effective
antiviral therapies to treat patients with HBV recurrence.
(Liver Transpl 2001;7:504-510.)
Hepatitis B virus (HBV)-related liver disease ac-counts for approximately 200 of the 4,500 liver
transplantations (LTs) performed each year in the
United States.1,2 In the absence of adequate immuno-
prophylaxis, graft reinfection occurs in 80% to 100% of
hepatitis B surface antigen–positive (HBsAg) liver
transplant recipients and is frequently associated with
poor clinical outcomes.3,4 The introduction of long-
term high-dose hepatitis B immunoglobulin (HBIg)
prophylaxis with or without lamivudine has led to a
marked reduction in the rate of graft reinfection and
improved patient and graft survival.5-8 However, high-
risk patients who are HBV DNA or hepatitis B e
antigen (HBeAg) before LT remain at significant risk
for developing graft reinfection and potentially severe
liver disease.3,5
High levels of viral replication are frequently noted
in liver transplant recipients with HBV infection.3,4,9,10
Although reduction in immunosuppression has proven
beneficial, antiviral treatment may still be needed in
some patients.11,12 Treatment with interferon (IFN)-
has been disappointing, with no consistent effect on HBV
replication or liver histological characteristics.13,14 In ad-
dition, such potentially serious side effects of IFN as
myelotoxicity and neuropsychiatric toxicity have lim-
ited the use of IFN in liver transplant recipients.14 Con-
versely, several studies have shown that lamivudine, a
potent inhibitor of HBV polymerase, is a safe and po-
tentially effective therapy with biochemical, virological,
and histological improvements reported in liver trans-
plant recipients with HBV.15,16 Case reports also suggest
that liver transplant recipients with fibrosing cholestatic
hepatitis may benefit from lamivudine therapy.17,18
However, prolonged administration of lamivudine
can lead to virological breakthrough because of the
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emergence of drug-resistant strains of HBV, termed
YMDD mutants.19,20 The incidence of drug resistance
increases with the duration of treatment, but appears to
be greater in immunosuppressed patients with high lev-
els of HBV replication compared with other patients
administered lamivudine.15,21 Although YMDD mu-
tants are replication defective in vitro compared with
wild-type HBV, severe liver disease has been reported in
some patients with YMDD-related virological break-
through post-LT.15,19,22,23
The primary aim of this study is to assess the safety
and efficacy of extended lamivudine monotherapy in 33
liver transplant recipients with active HBV infection.
Patients and Methods
Patient Population
Liver transplant recipients with established HBV infection at
any US clinical site were eligible for participation in this
open-label prospective study conducted between January
1996 and June 1999. Key inclusion criteria included age older
than 13 years, prior LT, and persistently detectable HBsAg for
more than 12 weeks post-LT or HBsAg positive (HBsAg)
and HBV DNA for more than 4 weeks post-LT. All subjects
were required to be at risk for progressive liver injury based on
any of the following 3 pretreatment liver biopsy findings:
active necroinflammatory changes consistent with HBV-
related hepatitis, hepatitis B core antigen–positive hepato-
cytes on immunohistochemical staining, or evidence of fibro-
sing cholestatic hepatitis. Exclusion criteria were acute liver
failure, pregnancy or breast-feeding, severe pancreatitis, or the
need for mechanical intubation.
Study Protocol
Informed consent for study participation was obtained from
eligible subjects per local institutional review board guide-
lines. Enrolled patients were prospectively monitored at
weeks 0, 2, 4, 8, 12, and 16 and every 8 weeks thereafter until
study completion. Centralized laboratory monitoring (Co-
vance Laboratories, Indianapolis, IN) included complete
blood counts and serum electrolyte and amylase levels, as well
as serum aspartate aminotransferase, alanine aminotransferase
(ALT), bilirubin, and albumin levels. Hepatitis B serological
tests, including HBsAg, antibody to HBsAg (anti-HBs),
HBeAg, and antibody to HBeAg (anti-HBe), were measured
every 8 weeks using commercially available enzyme-linked
immunosorbent assays. Serum HBV DNA levels were mea-
sured every 16 weeks using the Chiron branched-chain am-
plification (bDNA) assay (Chiron Corp, Emeryville, CA)
with a lower limit of detection of 0.7 mEq/mL (7  105
genome equivalents per milliliter).
Open-label lamivudine (Epivir-HBV; GlaxoSmithKline,
Research Triangle Park, NC) was orally self-administered by
the patients as a single 100-mg tablet daily. Because lamivu-
dine is renally cleared, patients with an estimated creatinine
clearance less than 50 mL/min derived from the Cockroft-
Gault equation were administered a reduced dose of lamivu-
dine oral suspension.24 Patient compliance was assessed by
reviewing drug diaries and unused vials at each study visit.
Safety assessment included recording all patient deaths, ad-
verse events, and clinically significant laboratory test result
abnormalities at each study visit regardless of attributability to
study drug. Lamivudine therapy was discontinued at the dis-
cretion of the local investigator if patients were not believed to
be deriving benefit.
Study End Points
All subjects were prospectively followed up until death, dis-
continuation of lamivudine therapy, or last available follow-
up. The primary efficacy end point was virological response,
defined as a loss of previously detectable serum HBV DNA
using the bDNA assay. Secondary end points included
HBeAg loss and seroconversion to anti-HBe, HBsAg loss and
seroconversion to anti-HBs, serum ALT level normalization,
assessment of improvement in serum albumin and bilirubin
levels in all patients and those with low albumin and elevated
bilirubin levels pretreatment, and safety assessments. Break-
through infection was defined as the reappearance of detect-
able serum HBV DNA using the bDNA assay for 2 consecu-
tive visits, including the last visit, in a patient who was HBV
DNA at baseline with viral levels suppressed to undetectable
during treatment or those who had detectable HBV DNA at
the last visit. When breakthrough infection was suspected, the
clinical investigator was encouraged to send the patient’s sera
to the central virology laboratory for additional studies, in-
cluding YMDD genotyping by polymerase chain reaction
(PCR)-based methods, as previously reported.25
Data Analysis
Data were entered into a centralized database using SAS soft-
ware (SAS Institute, Cary, NC). Efficacy and safety data were
analyzed according to a predefined data analysis plan. Explor-
atory analyses were performed to assess the impact of virolog-
ical breakthrough on efficacy and safety outcomes. Quantita-
tive data are described using summary measures of central
tendencies; P for within-subject changes at last study visit
(compared with baseline) were derived using a paired t-test or
sign test for normally distributed and non–normally distrib-
uted variables, respectively. Discrete measurements are based
on contingency tables, and Chi-squared test was used to ob-
tain P. All P are intended to be descriptive in nature because
the sample size was not based on power considerations. P less
than .05 is considered statistically significant.
Results
Patient Population and Disposition
Thirty-three HBsAg liver transplant recipients at 14
US clinical sites were enrolled. The median time from
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LT to study entry was 51 months (range, 6 to 123
months; Table 1). At the time of study enrollment,
none of the 33 patients was administered HBIg for
post-LT immunoprophylaxis. Serum markers of HBV
replication before treatment included detectable HBsAg
in all patients, detectable HBeAg in 75% of patients
(24 of 32 patients), and detectable HBV DNA by
bDNA testing in 94% of patients (29 of 31 patients)
tested. Eighty-four percent of patients (26 of 31 pa-
tients) had elevated pretreatment serum ALT levels,
whereas 39% (12 of 31 patients) had elevated serum
bilirubin levels and 29% (9 of 31 patients) had low
serum albumin levels at entry. Six patients were coin-
fected with hepatitis C virus, and 1 patient was coin-
fected with hepatitis D virus. Immunosuppressive med-
ications were not altered as a result of participation in
this study and included corticosteroids (79%), cyclo-
sporine (73%), tacrolimus (18%), and azathioprine
(21%). Three subjects were administered open-label
famciclovir (Famvir; SmithKline Beecham, Pittsburgh,
PA) for HBV infection at entry, which was continued
throughout the duration of the study in 1 patient.
During the course of the study, lamivudine treat-
ment was prematurely discontinued in 7 patients, 1
patient died of an unrelated cause, and 25 patients were
treated until study termination (Fig. 1). Lamivudine
treatment was prematurely discontinued because of in-
vestigator preference to switch to a commercially avail-
able formulation of lamivudine (3 patients), patient
relocation (1 patient), sleep disturbance (1 patient),
increased liver enzyme levels (1 patient), and lack of
improvement in liver enzyme levels (1 patient).
Virological Efficacy Response
The median duration of lamivudine treatment in the 33
patients was 85 weeks (range, 16 to 142 weeks). Median
serum HBV DNA levels at entry (2,816 mEq/mL;
range, 0.35 to 106,700 mEq/mL) became undetectable
within 16 weeks of starting therapy and were signifi-
cantly lower at last follow-up compared with entry
(2 mEq/mL; range, 0.35 to 4,675 mEq/mL; P  .0279;
Fig. 2). The proportion of patients who became HBV
DNA negative was 72% at 6 months, 50% at 12
months, and 36% at last visit. Seven of the 18 patients
who were HBV DNA at the last study visit were
confirmed to have YMDD variants, whereas the other
11 patients did not undergo testing for YMDD vari-
ants. During the study, 9% of patients (3 of 23 patients)
lost previously detectable HBeAg at the last visit, and 1
of these patients developed anti-HBe. There was no loss
Table 1. Pretreatment Clinical Features of 33 Liver
Transplant Recipients With Active HBV Infection
Demographics







Median time from LT (mo) 51 (65-123)
HBeAg 24 (75)
HBV DNA* 29/31 (94)
Median HBV DNA (mEq/mL) 2,816 (0.35-106,700)
Median serum ALT (IU/L) 80 (17-276)
Median serum bilirubin (mg/dL) 1.0 (0.3-4.5)
Median serum albumin (g/dL) 3.6 (2.0-4.4)
NOTE. Values expressed as number (range) or number (per-
cent).
*Two additional patients were HBV DNA pretreatment
using PCR-based assays performed locally.
Figure 1. Patient disposition during the study. The 2
early discontinuations were because of investigator pref-
erence (1 patient) and increased liver enzyme levels (1
patient), whereas the 5 late discontinuations were because
of investigator preference (3 patients), patient relocation
(1 patient), and sleep disturbance (1 patient).
Figure 2. Median serum HBV DNA and ALT levels dur-
ing lamivudine treatment of 33 liver transplant recipients
with active HBV infection.
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of previously detectable HBsAg or development of anti-
HBs in any of the treated subjects.
Clinical Efficacy Response
The median serum ALT level at the last visit was 51
IU/L, with a range of 18 to 339 IU/L, which was sig-
nificantly lower than pretreatment levels (P  .0093,
paired t-test). Serum ALT levels normalized in 27%
of patients (7 of 26 patients) with previously elevated
levels, and the last serum ALT level was lower than
the pretreatment value in 78% of treated patients
(Fig. 2). Median serum albumin and bilirubin levels
remained stable in the entire cohort during the study.
However, in the 12 patients with an elevated pre-
treatment bilirubin level (1.4 mg/dL) and the 9
patients with a low serum albumin level (3.5 g/dL),
a statistically significant improvement was observed
at last follow-up compared with pretreatment (P 
.0273 and P  .0263, respectively, sign test; Fig. 3).
Complications of liver disease reported during the
course of treatment included 1 patient with a variceal
bleed (patient no. 6; Table 3), 1 patient with an
episode of hepatic encephalopathy, and 1 patient
with hepatic encephalopathy and ascites (patient
no. 12, Table 3) that resolved over time. None of
these episodes of decompensation were believed to be
caused by the administration of lamivudine. The
single patient administered lamivudine in combina-
tion with famciclovir was treated for 103 weeks. Se-
rum ALT levels improved from 254 IU/L pretreat-
ment to 34 IU/L at last follow-up, whereas HBV
DNA levels remained unchanged at 275.5 mEq/mL
pretreatment and 938.7 mEq/mL at the last study
visit.
Virological Breakthrough
Virological breakthrough was detected in 13 of 29 pa-
tients (45%) with adequate available HBV DNA data
during the study (Tables 2 and 3). Patients with viro-
logical breakthrough were treated for a median of 119
weeks compared with a median of 59.3 weeks in pa-
tients without virological breakthrough (P  .0047).
The median duration of lamivudine therapy before vi-
rological breakthrough was 61 weeks (range, 26 to 118
weeks). Seven of the 13 patients (54%) with virological
breakthrough were confirmed to have PCR-detectable
YMDD mutants. Twelve of the 13 patients with viro-
logical breakthrough were alive at last visit; only 1 pa-
tient (patient no 1, Table 3) died of an unrelated cere-
bral hemorrhage.
Clinical, virological, and biochemical parameters of
patients with and without virological breakthrough
were similar at entry (Table 2). As expected, serum
HBV DNA levels were greater at the last visit in patients
with virological breakthrough compared with patients
without virological breakthrough, but the median HBV
DNA level remained lower than the pretreatment value




(n  13) P *
Median time from LT (mo) 51 (6-123) 69 (12-109)
Lamivudine (wk) 59.3 (16-133) 119 (41-142) .0047
HBV DNA (mEq/mL) 5,339/0† 2,226/78.5 .0054
Serum ALT (IU/L) 82/39 77/53 .519
Serum bilirubin (mg/dL) 1.0/0.9 1.1/1.0 .855
Serum albumin (g/dL) 3.6/3.9 3.6/3.6 .0411
NOTE. Values expressed as median entry/last value or number (range).
* Comparison of laboratory values of patients at the last visit with and without virologic breakthrough performed using Wilcoxon’s
rank-sum test.
† Undetectable by Chiron bDNA assay.
Figure 3. Median serum bilirubin and albumin levels
in patients administered lamivudine with abnormal
values at study entry. Twelve patients had elevated
pretreatment bilirubin levels (>1.4 mg/dL) and 9 pa-
tients had low pretreatment serum albumin levels
(<3.5 g/dL).
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in both patient subgroups. Median serum ALT and
bilirubin levels at last follow-up in patients with and
without virological breakthrough were not significantly
different, whereas albumin levels were lower in patients
with virological breakthrough.
Safety
One patient died during this study of a cerebral hem-
orrhage after 21 months of lamivudine therapy, which
was not believed to be related to the study medication.
Serious adverse events were reported in 11 patients. Of
note, 7 of the 13 patients with virological breakthrough
(54%) reported serious adverse events during treatment
that were unrelated to liver disease or the study drug
compared with 2 of the 16 patients (12%) without
virological breakthrough (P  .041, Fischer’s exact
test). Grades 3 and 4 laboratory abnormalities were
reported in 23 patients and were not more common in
patients with virological breakthrough compared with
patients without virological breakthrough.
Discussion
Several studies suggest that lamivudine may be a safe
and effective treatment for liver transplant recipients
with active HBV infection.15,16 In our study, lamivu-
dine was well tolerated and not associated with an iden-
tified pattern of drug-attributable adverse events. As a
potent inhibitor of HBV polymerase, lamivudine treat-
ment led to a rapid suppression of HBV replication in
this group of immunosuppressed liver transplant recip-
ients with high pretreatment serum HBV DNA levels
(Fig. 2). Although follow-up liver biopsies were not
performed in our study, serum ALT levels tended to
improve over time in patients with elevated levels pre-
treatment. In addition, serum albumin and bilirubin
levels significantly improved in patients with abnormal
levels pretreatment, suggesting that lamivudine-medi-
ated suppression of HBV replication can result in im-
proved liver disease in patients with ongoing HBV-
related graft injury (Fig. 3).
Our study represents the longest duration of lami-
vudine treatment in a large group of liver transplant
recipients with HBV reported in the literature (Table 4).
Not surprisingly, 45% of our patients developed evi-
dence of virological breakthrough after a median of 61
weeks of lamivudine treatment. The majority of these
patients were shown to have developed PCR-detectable
YMDD mutants, which have been associated with
lamivudine resistance in vitro and diminished clinical
response to continued lamivudine therapy.20,21 HBV
genotyping results in this study are similar to those
reported in another study of transplant recipients.15
The greater incidence of virological breakthrough in
our patient population may be caused in part by the
longer duration of lamivudine treatment in our study.
Pretreatment demographic characteristics and time












Mutants*Pre Last Pre Last
1 42/94 45 53 6,227 902.9 Death† B, C
2 114/130 131 90 2,816 3.1 —
3 118/134 135 67 712.5 1.4 —
4 89/142 77 18 187.1 71.8 B, C
5 113/134 56 22 976.7 1.2 —
6 63/128 172 80 3,765 63.6 Variceal bleed B, C
7 85/127 84 58 3,175 4,675 C
8 54/119 169 82 509 134.9 —
9 50/114 40 36 6,731 1,048 B, C
10 43/103 70 31 3,680 78.5 B, C
11 61/100 69 99 2,226 353.5 B, C
12 27/68 53 49 1,301 2.6 Encephalopathy, ascites —
13 26/40 89 47 1,381 132.8 —
* YMDD mutants determined in 7 of the 13 patients using restriction fragment length polymorphism.25 B mutants refer to viral isolates
with mutations identified in the B domain, L528M. C mutants refer to viral isolates with mutations identified in the C domain, including
M552V and M552I.
† Death from unrelated cerebral hemmorhage.
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from LT were not predictive of virological break-
through, but patients with virological breakthrough
were administered lamivudine for a longer time than
those without virological breakthrough. Nonetheless,
serum HBV DNA levels at last follow-up remained
lower than pretreatment levels in 12 of the 13 patients
with virological breakthrough. In addition, serum ALT
and bilirubin levels were similar to those of patients
without virological breakthrough at the last follow-up
(Table 2). During a median study follow-up of 86
weeks, none of the patients in our series have required
re-LT.
Our observations are in contrast to those of Perrillo
et al15 and others who reported that a subgroup of
patients with YMDD-associated virological break-
through may develop worsening liver function and he-
patic insufficiency during relatively short-term follow-
up.23,26 The reason for a lack of clinical deterioration in
our patients is unclear because the biochemical severity
of illness before treatment was similar.15,26 Interest-
ingly, the median time to develop virological break-
through in our study was 61 weeks compared with 32
weeks in the study of Perrillo et al,15 although pretreat-
ment serum HBV DNA levels and degree of immuno-
suppression appeared similar.
In summary, the results of our study show that pro-
longed lamivudine treatment is well tolerated in liver
transplant recipients with active HBV infection. Lami-
vudine treatment was associated with a significant im-
provement in serum albumin and bilirubin levels in a
subgroup of patients with more severe biochemical ab-
normalities at baseline. Randomized controlled trials
are needed to define which patients with hepatitis B
after LT may benefit from antiviral therapy. As addi-
tional antiviral agents become available for clinical in-
vestigation, liver transplant recipients at high risk for
poor clinical outcomes deserve further study through
controlled trials in which all treatment arms use puta-
tively active agents (or combinations of agents). The
relatively high rate of virological breakthrough encoun-
tered with prolonged lamivudine monotherapy in our
study and others indicates that studies of combination
antiviral therapy are desirable for this patient group. For
lamivudine-treated patients with virological break-
through and evidence of a loss of clinical response,
controlled trials of potential salvage therapies are war-
ranted. Adefovir dipivoxil, another potent inhibitor of
HBV polymerase, appears to be effective in patients
with lamivudine-resistant strains of HBV.27,28 How-
ever, further studies clarifying the potential nephrotox-
icity of adefovir are needed. Other potent nucleoside
analogues, such as entecavir, may also prove useful in
combination with lamivudine in liver transplant recip-
ients with HBV, but these agents will also require fur-
ther study as single agents to establish their safety and
efficacy.29,30
In conclusion, our study results further establish that
long-term outcomes for patients with advanced HBV
undergoing LT are improving through advances in the
prevention of viral recurrence (with HBIg and lamivu-
dine) and the availability of safe and effective antiviral
therapies for patients with recurrent HBV after LT.
Acknowledgment
The US Lamivudine Compassionate Use Study Group inves-
tigators who contributed to this study include: Bruce Bacon,
Saint Louis University; Alfred Baker, University of Chicago
Medical Center; Vijayan Balan, University of Pittsburgh;
Martin Black, Temple University; Jeremiah Donovan, Uni-
versity of Nebraska; Gregory Everson, University of Colorado
Health Sciences; Robert Fontana, University of Michigan;
Robert Gish, California Pacific Medical Center; Hie-Won
Hann, Jefferson Medical College; Kris V. Kowdley, Univer-
sity of Washington, Seattle; Dirk van Leeuwen, University of
Alabama at Birmingham; Howard P. Mansour, Kelsey Re-
search Foundation, Houston; John Pirsch, University of Wis-










Perrillo et al15 52 49 (2-142) 52* 27
Malkan et al16† 15 19 (1-84) 106 (52-156) 13
Nery et al31‡ 8 17 (2-51) 108 (44-156) 37
Fontana et al 33 51 (6-123) 85 (16-142) 45
* All patients had recurrent hepatitis B and received 52 weeks of lamivudine therapy.
† Twenty-seven percent of patients were electively converted from HBIg to lamivudine for post-LT prophylaxis.
‡ HBIG treatment failed in all patients and 2 patients were administered concomitant famciclovir.
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